Evidence map›Paper›PMID 21385431›Full record

ArticleBMC neuroscience2011

Proteomic assessment of a cell model of spinal muscular atrophy.

Chia-Yen Wu, Dosh Whye, Lisa Glazewski, Leila Choe, Douglas Kerr, Kelvin H Lee, Robert W Mason, Wenlan Wang

Open access · goldAbstract read
In one paragraph

Article in BMC neuroscience, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Chia-Yen WuDepartment of Biological Science, University of Delaware, Newark, DE, USA.
Dosh Whye
Lisa Glazewski
Leila Choe
Douglas Kerr
Kelvin H Lee
Robert W Mason
Wenlan Wang
Alfred I. duPont Hospital for Children · USBiotechnology Institute · USUniversity of Delaware · USBiogen (United States) · USColumbia University Irving Medical Center · US

Funding

VOLUMETRIC BREAST DENSITY ESTIMATION USING BREAST SURFACE RECONSTRUCTEDP20RR016472 · NCRR · UNIVERSITY OF DELAWARE · PI STANHOPE, STEVEN J. · 2001 to 2011
$37.6M
TRAJECTORIES OF CHANGE IN BMI STATUS IN EARLY CHILDHOODP20RR020173 · NCRR · NEMOURS CHILDREN'S HOSPITAL, DELAWARE · PI MASON, ROBERT · 2004 to 2011
$14.9M
NCRR NIH HHS 2 P20 RR016472-10NCRR NIH HHS 5 P20 RR020173-04
6 · The paper itself

Abstract

backgroundDeletion or mutation(s) of the survival motor neuron 1 (SMN1) gene causes spinal muscular atrophy (SMA), a neuromuscular disease characterized by spinal motor neuron death and muscle paralysis. Complete loss of the SMN protein is embryonically lethal, yet reduced levels of this protein result in selective death of motor neurons. Why motor neurons are specifically targeted by SMN deficiency remains to be determined. In this study, embryonic stem (ES) cells derived from a severe SMA mouse model were differentiated into motor neurons in vitro by addition of retinoic acid and sonic hedgehog agonist. Proteomic and western blot analyses were used to probe protein expression alterations in this cell-culture model of SMA that could be relevant to the disease.

resultsWhen ES cells were primed with Noggin/fibroblast growth factors (bFGF and FGF-8) in a more robust neural differentiation medium for 2 days before differentiation induction, the efficiency of in vitro motor neuron differentiation was improved from ~25% to ~50%. The differentiated ES cells expressed a pan-neuronal marker (neurofilament) and motor neuron markers (Hb9, Islet-1, and ChAT). Even though SMN-deficient ES cells had marked reduced levels of SMN (~20% of that in control ES cells), the morphology and differentiation efficiency for these cells are comparable to those for control samples. However, proteomics in conjunction with western blot analyses revealed 6 down-regulated and 14 up-regulated proteins with most of them involved in energy metabolism, cell stress-response, protein degradation, and cytoskeleton stability. Some of these activated cellular pathways showed specificity for either undifferentiated or differentiated cells. Increased p21 protein expression indicated that SMA ES cells were responding to cellular stress. Up-regulation of p21 was confirmed in spinal cord tissues from the same SMA mouse model from which the ES cells were derived.

conclusionSMN-deficient ES cells provide a cell-culture model for SMA. SMN deficiency activates cellular stress pathways, causing a dysregulation of energy metabolism, protein degradation, and cytoskeleton stability.

Indexed as

AnimalsAntibodiesCell DifferentiationCell Line, TransformedDisease Models, AnimalEmbryo, MammalianFibroblast Growth Factor 8Fibroblast Growth FactorsGene Expression RegulationGreen Fluorescent ProteinsMiceMice, TransgenicMotor NeuronsMuscular Atrophy, SpinalNerve Tissue ProteinsProteomeAntibodiesFgf8 protein, mouseFibroblast Growth Factor 8Fibroblast Growth FactorsGreen Fluorescent ProteinsNerve Tissue ProteinsProteomeSurvival of Motor Neuron 1 Protein

Identifiers

PMID21385431
PMCPMC3063191
OpenAlexW2134569854

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.